GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » PS Ratio

Entrada Therapeutics (Entrada Therapeutics) PS Ratio : 3.24 (As of Apr. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Entrada Therapeutics's share price is $12.45. Entrada Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.84. Hence, Entrada Therapeutics's PS Ratio for today is 3.24.

Good Sign:

Entrada Therapeutics Inc stock PS Ratio (=3.17) is close to 2-year low of 3.16

The historical rank and industry rank for Entrada Therapeutics's PS Ratio or its related term are showing as below:

TRDA' s PS Ratio Range Over the Past 10 Years
Min: 3.16   Med: 6.43   Max: 22.12
Current: 3.33

During the past 5 years, Entrada Therapeutics's highest PS Ratio was 22.12. The lowest was 3.16. And the median was 6.43.

TRDA's PS Ratio is ranked better than
74.29% of 992 companies
in the Biotechnology industry
Industry Median: 8.85 vs TRDA: 3.33

Entrada Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $1.25. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.84.

Back to Basics: PS Ratio


Entrada Therapeutics PS Ratio Historical Data

The historical data trend for Entrada Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entrada Therapeutics PS Ratio Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - - 3.87

Entrada Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 18.59 11.40 6.11 3.87

Competitive Comparison of Entrada Therapeutics's PS Ratio

For the Biotechnology subindustry, Entrada Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entrada Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's PS Ratio falls into.



Entrada Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Entrada Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=12.45/3.84
=3.24

Entrada Therapeutics's Share Price of today is $12.45.
Entrada Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Entrada Therapeutics  (NAS:TRDA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Entrada Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Entrada Therapeutics (Entrada Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6 Tide Street, Boston, MA, USA, 02210
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Executives
Dipal Doshi director, officer: President and CEO C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Kory James Wentworth officer: Chief Financial Officer 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Nathan J Dowden officer: Chief Operating Officer 6 TIDE STREET, BOSTON MA 02210
Nerissa Kreher officer: Chief Medical Officer C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman director C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Natarajan Sethuraman officer: Chief Scientific Officer 6 TIDE STREET, BOSTON MA 02210
Bernhardt G Zeiher director ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
John F Crowley director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142

Entrada Therapeutics (Entrada Therapeutics) Headlines